Patents by Inventor Yaocheng Rui

Yaocheng Rui has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Application of cyclic dinucleotide (cGAMP) in anti-tumor field
    Patent number: 10092592
    Abstract: The present invention belongs to the field of medicine technology, particularly relating to an application of cyclic dinucleotide (cGAMP) in tumor treatment. Researches carried out in the present invention show that, cGAMP can inhibit growth of many types of tumor cells, with remarkable anti-tumor effect, thus, it can be used in preparation of anti-tumor drugs; and the prepared anti-tumor drugs have low toxicity and favorable effect. Proved by a subcutaneous tumor model in nude mice, cGAMP has a remarkable inhibition effect on tumors of human gastric carcinoma cell line MNK-45, human lung adenocarcinoma cell line A549, human colorectal carcinoma cell line Lovo, human hepatocellular carcinoma cell line SMMC-7721, human prostatic carcinoma cell line PC-3 and human pancreatic carcinoma cell SW1990, which are subcutaneously implanted in nude mice, and also proved by animal acute toxicity experiment. cGAMP has a relatively low acute toxicity, therefore and may be used for preparing anti-tumor drugs.
    Type: Grant
    Filed: April 20, 2015
    Date of Patent: October 9, 2018
    Assignee: Fudan University
    Inventors: Xiangshi Tan, Tiejun Li, Qiming Xu, Jie Pan, Yaocheng Rui, Hao Cheng, Yuefan Zhang
  • ANTITUMOR USE OF CYCLIC DINUCLEOTIDE CGMP
    Publication number: 20170196902
    Abstract: The present invention belongs to the field of medicine technology, particularly relating to an application of cyclic dinucleotide (cGAMP) in tumor treatment. Researches carried out in the present invention show that, cGAMP can inhibit growth of many types of tumor cells, with remarkable anti-tumor effect, thus, it can be used in preparation of anti-tumor drugs; and the prepared anti-tumor drugs have low toxicity and favorable effect. Proved by a subcutaneous tumor model in nude mice, cGAMP has a remarkable inhibition effect on tumors of human gastric carcinoma cell line MNK-45, human lung adenocarcinoma cell line A549, human colorectal carcinoma cell line Lovo, human hepatocellular carcinoma cell line SMMC-7721, human prostatic carcinoma cell line PC-3 and human pancreatic carcinoma cell SW1990, which are subcutaneously implanted in nude mice, and also proved by animal acute toxicity experiment. cGAMP has a relatively low acute toxicity, therefore and may be used for preparing anti-tumor drugs.
    Type: Application
    Filed: April 20, 2015
    Publication date: July 13, 2017
    Applicant: FUDAN UNIVERSITY
    Inventors: Xiangshi TAN, Tiejun LI, Qiming XU, Jie PAN, Yaocheng RUI, Hao CHENG, Yuefan ZHANG
  • Method for treating myocardial ischemia
    Patent number: 8343921
    Abstract: Use of polypeptide micromolecule MLIF in preparing medicine for preventing and treating myocardial ischmia, where amino acid sequence of the polypeptide micromolecule MLIF is Met-Gln-Cys-Asn-Ser (SEQ ID NO:1).
    Type: Grant
    Filed: January 23, 2012
    Date of Patent: January 1, 2013
    Assignee: Shanghai Bajiayi Pharmaceutical Science and Technology Co. Ltd.
    Inventors: Yaocheng Rui, Tiejun Li, Pengyuan Yang, Yuefan Zhang
  • Use of Polypeptide Micromolecule MLIF in Preparing Medicine for Preventing and Treating Myocardial Ischemia
    Publication number: 20120122786
    Abstract: Use of polypeptide micromolecule MLIF in preparing medicine for preventing and treating myocardial ischmia, where amino acid sequence of the polypeptide micromolecule MLIF is Met-Gln-Cys-Asn-Ser (SEQ ID NO:1).
    Type: Application
    Filed: January 23, 2012
    Publication date: May 17, 2012
    Applicant: THE SECOND MILITARY MEDICAL UNIVERSITY, PLA
    Inventors: Yaocheng Rui, Tiejun Li, Pengyuan Yang, Yuefan Zhang